title: [Pneumocystis carinii pneumonia during therapy with 2-chlorodeoxyadenosine (2-CDA)].
abstract: We report the case of a 70-year-old patient with B-cell chronic lymphocytic leukemia. During therapy with the new purine analog 2-chloro-deoxyadenosine (2-CDA) the patient developed Pneumocystis carinii pneumonia (PCP). Although the mechanism of action of 2-CDA suggests the incidence of opportunistic infections and therefore pneumocystis pneumonia, this is the first case of PCP among 140 patients of the Swiss study of 2-CDA. The mechanism of action of 2-CDA is described and the occurrence of PCP among patients without acquired immunodeficiency syndrome is discussed.
authors.affiliation: Departement Innere Medizin, Kantonsspital Basel.
authors.forename: C
authors.initials: C
authors.lastname: Haberthür
authors.forename: M
authors.initials: M
authors.lastname: Pless
authors.forename: A
authors.initials: A
authors.lastname: Tichelli
authors.forename: A
authors.initials: A
authors.lastname: Gratwohl
authors.forename: B
authors.initials: B
authors.lastname: Speck
authors.forename: D C
authors.initials: DC
authors.lastname: Betticher
mesh_terms: D000368:Aged; D017338:Cladribine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D011020:Pneumonia, Pneumocystis / Q000150:complications*
chemical_list: D017338:Cladribine
vernacular_title: Pneumocystis-carinii-Pneumonie unter Therapie mit 2-Chlorodeoxyadenosin (2-CDA).